+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 0 - 1Month
All Genders
ID07324941

Using EEG to Guide Timing for Stopping Caffeine Treatment in Premature Infants with Apnea

Led by Uludag University · Updated on 2026-05-01

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether electroencephalography EEG can reliably assess brain maturation in preterm infants to guide the safe stopping of caffeine therapy without causing a return of apnea. The study focuses on infants born prematurely who are receiving caffeine to manage apnea of prematurity, a condition causing pauses in breathing. The study involves observing infants who have been treated with caffeine. EEG assessments will be conducted when it is time to consider stopping caffeine treatment, to help determine if the infants brain has matured enough to discontinue therapy safely. There are no experimental treatments instead, the study monitors and evaluates EEG data alongside clinical outcomes. Participants will be monitored from enrollment until four weeks after caffeine therapy ends. Researchers will evaluate apnea risk after stopping caffeine by reviewing EEG results and clinical observations. The study includes infants born before 37 weeks gestation who have received caffeine treatment, with follow-up assessments to ensure safety and gather reliable data on apnea recurrence.

CONDITIONS

Brief Title

The Role of Electroencephalography in Caffeine Discontinuation Timing in Premature Infants

Research Team

S

Salih Çağrı Çakır

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here